Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
Table 1
Baseline characteristics of protease inhibitor naïve patients in the ODIN trial.
Darunavir/ritonavir 800/100 mg once daily
Darunavir/ritonavir 600/100 mg twice daily
135
137
Age (years): median (range)
38 (18–70)
38 (18–77)
Female
49 (36.3%)
47 (34.3%)
CD4 count <200 cells/µL
59 (43.7%)
54 (39.4%)
HIV-1 RNA ≥100,000 copies/mL
9 (6.7%)
13 (9.5%)
Race
Black
35 (25.9%)
38 (27.3%)
Caucasian
27 (20.0%)
39 (28.5%)
Oriental/Asian
41 (30.4%)
29 (21.2%)
Other
32 (23.7%)
31 (22.6%)
Region
Africa
22 (16.3%)
23 (16.8%)
Asia
41 (30.4%)
28 (20.4%)
Europe/Australia
11 (8.1%)
12 (8.8%)
N America
11 (8.1%)
16 (11.7%)
S America
50 (37.0%)
58 (42.3%)
CDC Stage 3 or 4
53 (39.3%)
50 (36.5%)
HIV-1 subtype
B
64 (47.4%)
78 (56.9%)
A1
1 (0.7%)
0
C
26 (19.3%)
26 (19.0%)
CRF01_AE
37 (27.4%)
27 (19.7%)
CRF02_AG
2 (1.5%)
0
CRF012_BF
3 (2.2%)
2 (1.5%)
F1
2 (1.5%)
4 (2.9%)
Fully active NRTIs used
0
7 (6%)
9 (7%)
1
34 (27%)
35 (27%)
≥2
85 (67%)
88 (67%)
All results shown are (%), unless otherwise stated. Baseline genotyping results were available. There were 9 patients in the 800/100 mg OD arm and 5 in the 600/100 mg BID arm who did not have genotypes available at the baseline visit.
